TTX-080 + FOLFIRI + cetuximab

TTX-080 + FOLFIRI + cetuximab is an investigational cancer therapy combining three agents: - **TTX-080:** a first-in-class monoclonal antibody that blocks the immunosuppressive molecule HLA-G, designed to reverse immune tolerance and activate anti-tumor responses. - **FOLFIRI:** a chemotherapy regimen composed of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan, used to damage and destroy rapidly dividing cancer cells. - **Cetuximab:** an epidermal growth factor receptor (EGFR) inhibitor monoclonal antibody that blocks signaling pathways involved in tumor growth. This combination is being studied primarily for metastatic colorectal cancer (mCRC), particularly in patients who are microsatellite stable (MSS) and have wild-type (WT) RAS, BRAF, and HER2-negative tumors. Early clinical data indicate safety, tolerability, and promising anti-tumor activity, with immune activation observed in both peripheral blood and tumor tissue[1][3][5][7].